Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Raise 21.2 Billion Yen for Elmed Eisai Buyout
April 5, 2018
- Nihon Medi-Physics’ Project to Develop Labeled Antibody Therapeutics Selected for AMED’s CiCLE Grant Program
April 4, 2018
- Mochida Targets Sales of 103 Billion Yen in FY2020, Adding Gastroenterology to Priority Fields: New Biz Plan
April 4, 2018
- Fycompa Filed for Label Expansion in US for Pediatric Epilepsy
April 3, 2018
- Sanofi Seeks Asthma Indication for Dupixent in Japan
April 3, 2018
- Kyorin Nabs Rights to Sanwa Kagaku’s Nocturia Drug in Japan, Asia
April 3, 2018
- Apomorphine Sublingual Film Filed in US: Sunovion
April 3, 2018
- Daiichi Sankyo Alters Terms of Settlement over US Olmesartan Products Liability Litigation
April 3, 2018
- Ambicion Obtains Global Rights to RIKEN’s NKT Cell-Targeted Anti-Cancer Therapy
April 3, 2018
- Shionogi Trio Puts Up Add’l 1.8 Billion Yen Each for Peptide Therapeutics JV
April 2, 2018
- Zeria Files Iron Deficiency Med in Japan
April 2, 2018
- Nippon Kayaku Notches Top Court Victory for Elplat Damages Suit Too
April 2, 2018
- Kihito Takahashi Tapped as EVP of GSK Japan
April 2, 2018
- Lynparza Companion Diagnostic Approved in Japan: AZ
April 2, 2018
- Keytruda Filed for Tumor-Agnostic Indication in Japan
April 2, 2018
- Generic Use Rate at 68.9% in October-December: JGA
April 2, 2018
- Bayer Gives Update on Initiatives after Xarelto Survey Scandal
March 30, 2018
- Alliance with Nichi-Iko “Not Due to Pessimism about Generic Drug Business,” Will Expand Lineup: Eisai CEO
March 30, 2018
- Fujifilm to Gobble Up 2 Cell Culture Media Firms for US$800 million
March 30, 2018
- Takeda Gets Japan Rights to Ammonul from Valeant
March 29, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…